Hepatitis B Immunoglobulin P Behring

Hepatitis B Immunoglobulin P Behring

hepatitis b immunoglobulin


CSL Behring


Concise Prescribing Info
Human hepatitis B Ig
Hepatitis B immunoprophylaxis in non-immunised persons including those w/ incomplete or unknown status of vaccination, in haemodialysed patients until vaccination is effective, in the newborn of a HBV carrier mother or a mother w/ unknown HbsAg status & in persons who did not show an immune response after vaccination & for whom continuous prevention is necessary. Preferably as simultaneous prophylaxis along w/ a hepatitis B vaccine.
Dosage/Direction for Use
Non-immunised person 12 IU/kg body wt (at least 500 IU) IM as soon as possible after exposure w/in 72 hr. Haemodialysed patient 8-12 IU/kg body wt (max 500 IU) IM every 2 mth until seroconversion following vaccination. Newborn 30-100 IU/kg body wt (normally 1 mL) IM as soon as possible after birth, may be repeated until seroconversion following vaccination. No immune response after vaccination or as continuous prophylaxis Adult 500 IU; childn 8 IU/kg body wt. Administer every 2 mth.
Special Precautions
Observe patients for 20 min after administration. Pregnancy & lactation.
Adverse Reactions
Rarely, local reaction at inj site, allergic, generalized or CV reactions.
Drug Interactions
Allow 3 mth interval prior to vaccination of live attenuated virus vaccines. False positive result in serological testing.
ATC Classification
J06BB04 - hepatitis B immunoglobulin ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.
Hepatitis B Immunoglobulin P Behring vaccine (pre-filled syringe) 200 IU/mL
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in